A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Ethicon, Inc., a worldwide leader in surgical care, has announced its entrance into the barbed suture market with the launch of its new portfolio of STRATAFIX™ Knotless Tissue Control Devices, representing the next evolution in wound closure technology. With significantly more points of fixation than traditional sutures, STRATAFIX™ Devices give surgeons more consistent control over every pass (through the tissue), and combine the strength and security of interrupted closure with the efficiency of continuous closure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58405-ethicon-launches-stratafix-knotless-tissue-control-devices
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
Las familias se han transmitido de generación en generación los remedios caseros que han ayudado a que sus seres queridos se sientan atendidos, incluso durante esas etapas de congestión nasal y estornudos. Contar con un tazón de la famosa sopa de la abuela, o el cocimiento especial de la tía para curarse, contribuyen a que el cuerpo sane y a tranquilizar la mente. Recientemente, un grupo de madres blogueras hispanas revelaron los remedios a los que recurren sus familias para aliviar a sus seres queridos.
Para más, vaya a http://www.multivu.com/mnr/60905-kleenex-brand-tissue-favorite-family-home-remedies
A Firefly is lighting up operating rooms, making it easier for robotic surgeons to remove tumors. However, this Firefly is not the type that children catch in a jar during warm summer evenings. Instead, it’s a technology that uses a wavelength of light not visible to the human eye. A special dye is then injected which causes a bright green fluorescence of certain tissues, hence the name “Firefly.” This green glow lets surgeons clearly see the difference between cancerous and healthy tissue when performing surgery, allowing them to remove the tumor while saving the rest of the healthy organ.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342452-firefly-lighting-operating-rooms/
It’s normal to have uric acid in your body, but too much can increase your risk for gout – an extremely painful form of inflammatory arthritis that often presents with other health issues, including kidney disease, heart disease, diabetes and permanent joint and tissue damage. Despite this, just 10 percent of gout sufferers are being properly treated – and more than one-third have not had their uric acid checked in the past five years.
To raise awareness about the need for timely treatment for gout – including regular monitoring of serum uric acid (sUA) levels – the Gout & Uric Acid Education Society (GUAES) has introduced a new “Go for Six” campaign. The campaign urges those who have or who are at risk for gout to get their sUA levels checked every six months, and to work with their doctor to determine a treatment plan for controlling gout and keeping sUA levels to a healthy 6 mg/dL or below.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7420351-gout-uric-acid-go-for-six-campaign/
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
